EQ-5D outcomes in adults with autoimmune hepatitis: A GRADE-assessed systematic review and meta-analysis

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease that can substantially affect health-related quality of life (HRQoL). Although EQ-5D is widely used as a generic preference-based HRQoL instrument, EQ-5D outcomes in adults with AIH have not previously been synthesized in a focused systematic review. This review aimed to summarize EQ-5D outcomes in adults with AIH and assess the certainty of the available evidence using GRADE. A systematic review and meta-analysis was conducted in accordance with PRISMA and prospectively registered in PROSPERO (CRD420261334849). PubMed/MEDLINE, Scopus, Embase, and CENTRAL were searched from inception to 25 February 2026. Studies reporting EQ-5D utility/index, EQ-VAS, and/or domain-level outcomes in adults with AIH were included. Qualitative synthesis served as the primary interpretive framework, and quantitative synthesis was performed as an exploratory summary when appropriate. Certainty of evidence was assessed using GRADE. Five studies were included. Reported EQ-5D utility values ranged from 0.65 to 0.88, and EQ-VAS values ranged from 67.5 to 77.3 across studies. Exploratory random-effects synthesis yielded a pooled EQ-5D utility estimate of 0.80 (95% CI: 0.71 to 0.89; I² = 99.3%) and a pooled EQ-VAS estimate of 70.87 (95% CI: 67.28 to 74.46; I² = 93.9%). However, these pooled values should be interpreted as descriptive summaries of a highly heterogeneous evidence base rather than as stable benchmark estimates. Domain-level data from two studies suggested that pain/discomfort and anxiety/depression were the most frequently affected EQ-5D dimensions. Certainty of evidence was very low for all synthesized outcome groups. Available EQ-5D evidence in adults with AIH suggests an important HRQoL burden, particularly in the pain/discomfort and anxiety/depression domains. However, the evidence base is sparse, highly heterogeneous, and of very low certainty; therefore, pooled EQ-5D and EQ-VAS values should be interpreted as exploratory descriptive summaries rather than definitive benchmark estimates.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-05-18
DOI
https://doi.org/10.1038/s41598-026-53378-7
Primary Topic
Liver Diseases and Immunity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EQ-5D outcomes in adults with autoimmune hepatitis: A GRADE-assessed systematic review and meta-analysis

Nemani Sai Manasa, Mothishwaran Bhuvaneshwaran, S. Jennie, Parameswaran Karuppanan et al.
Scientific Reports
Liver Diseases and Immunity
article

EQ-5D outcomes in adults with autoimmune hepatitis: A GRADE-assessed systematic review and meta-analysis

Nemani Sai Manasa, Mothishwaran Bhuvaneshwaran, S. Jennie, Parameswaran Karuppanan, Hariharan Murugadoss
article en

Abstract

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease that can substantially affect health-related quality of life (HRQoL). Although EQ-5D is widely used as a generic preference-based HRQoL instrument, EQ-5D outcomes in adults with AIH have not previously been synthesized in a focused systematic review. This review aimed to summarize EQ-5D outcomes in adults with AIH and assess the certainty of the available evidence using GRADE. A systematic review and meta-analysis was conducted in accordance with PRISMA and prospectively registered in PROSPERO (CRD420261334849). PubMed/MEDLINE, Scopus, Embase, and CENTRAL were searched from inception to 25 February 2026. Studies reporting EQ-5D utility/index, EQ-VAS, and/or domain-level outcomes in adults with AIH were included. Qualitative synthesis served as the primary interpretive framework, and quantitative synthesis was performed as an exploratory summary when appropriate. Certainty of evidence was assessed using GRADE. Five studies were included. Reported EQ-5D utility values ranged from 0.65 to 0.88, and EQ-VAS values ranged from 67.5 to 77.3 across studies. Exploratory random-effects synthesis yielded a pooled EQ-5D utility estimate of 0.80 (95% CI: 0.71 to 0.89; I² = 99.3%) and a pooled EQ-VAS estimate of 70.87 (95% CI: 67.28 to 74.46; I² = 93.9%). However, these pooled values should be interpreted as descriptive summaries of a highly heterogeneous evidence base rather than as stable benchmark estimates. Domain-level data from two studies suggested that pain/discomfort and anxiety/depression were the most frequently affected EQ-5D dimensions. Certainty of evidence was very low for all synthesized outcome groups. Available EQ-5D evidence in adults with AIH suggests an important HRQoL burden, particularly in the pain/discomfort and anxiety/depression domains. However, the evidence base is sparse, highly heterogeneous, and of very low certainty; therefore, pooled EQ-5D and EQ-VAS values should be interpreted as exploratory descriptive summaries rather than definitive benchmark estimates.

Scientific Reports
SRM Institute of Science and Technology (IN)
Good health and well-being
Openalex Percentile: Top 7%
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.